Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Prosperity Consulting Group LLC

Prosperity Consulting Group LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 31.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,370 shares of the biopharmaceutical company's stock after selling 16,615 shares during the period. Prosperity Consulting Group LLC's holdings in Gilead Sciences were worth $2,495,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CarsonAllaria Wealth Management Ltd. grew its holdings in Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 238 shares in the last quarter. Private Wealth Management Group LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at about $29,000. Palisade Asset Management LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at about $29,000. Sachetta LLC purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at about $30,000. Finally, Financial Connections Group Inc. purchased a new stake in shares of Gilead Sciences during the second quarter valued at about $34,000. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Johanna Mercier sold 29,357 shares of the business's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares of the company's stock, valued at $6,614,559.40. The disclosure for this sale can be found here. Insiders have sold a total of 36,847 shares of company stock worth $3,002,940 in the last quarter. Company insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Royal Bank of Canada increased their price target on shares of Gilead Sciences from $72.00 to $74.00 and gave the company a "sector perform" rating in a research report on Wednesday, September 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Thursday, August 15th. BMO Capital Markets increased their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an "outperform" rating in a research report on Friday, August 9th. Raymond James raised shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and set a $93.00 price objective for the company in a research report on Monday, July 8th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday. Twelve analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $82.06.

Gilead Sciences Price Performance

GILD stock traded up $0.42 during midday trading on Friday, reaching $82.81. The stock had a trading volume of 6,530,266 shares, compared to its average volume of 7,168,032. The company's fifty day simple moving average is $75.48 and its 200 day simple moving average is $70.86. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The company has a market cap of $103.10 billion, a price-to-earnings ratio of 230.03, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.72%. Gilead Sciences's dividend payout ratio is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.